Does the hip powder of Rosa canina (rosehip) reduce pain in osteoarthritis patients? - a meta-analysis of randomized controlled trials

Osteoarthritis and Cartilage

Volumn 16, Issue 9, 2008, Pages 965-972

  Christensen, R ^a   Bartels, E M ^a,b   Altman, R D ^c   Astrup, A ^d   Bliddal, H ^a  

^a FREDERIKSBERG HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Dietary supplements; Hip, Herbal therapy; Knee; Meta analysis; Osteoarthritis; Rosa canina; Rosehip

Indexed keywords

ANALGESIC AGENT; HYBEN VITAL; LITOZIN; NUTRACEUTICAL; PLACEBO; PLANT EXTRACT; ROSA CANINA EXTRACT;

ANALGESIA; ARTHRALGIA; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DEFECATION DISORDER; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EFFECT SIZE; EMPIRICAL RESEARCH; GASTROINTESTINAL SYMPTOM; HUMAN; MAXIMUM LIKELIHOOD METHOD; MEDICINAL PLANT; META ANALYSIS; OSTEOARTHRITIS; OUTCOMES RESEARCH; PAIN ASSESSMENT; POWDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; ROSA CANINA; SCORING SYSTEM; STANDARDIZATION; SYSTEMATIC REVIEW; URTICARIA;

FEMALE; HUMANS; MALE; OSTEOARTHRITIS; PAIN; PHYTOTHERAPY; PLANT PREPARATIONS; POWDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; ROSA; TREATMENT OUTCOME;

EID: 49149083817     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2008.03.001     Document Type: Review

References (90)

1. Dieppe P.A., and Lohmander L.S. Pathogenesis and management of pain in osteoarthritis. Lancet 365 9463 (2005) 965-973
2. Altman R.D. Criteria for classification of clinical osteoarthritis. J Rheumatol Suppl 27 (1991) 10-12
3. Altman R., Asch E., Bloch D., Bole G., Borenstein D., Brandt K., et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 29 8 (1986) 1039-1049
4. Abramson S.B. Inflammation in osteoarthritis. J Rheumatol Suppl 70 (2004) 70-76
5. Spector T.D., Hart D.J., Nandra D., Doyle D.V., Mackillop N., Gallimore J.R., et al. Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum 40 4 (1997) 723-727
6. Jordan K.M., Arden N.K., Doherty M., Bannwarth B., Bijlsma J.W., Dieppe P., et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 62 12 (2003) 1145-1155
7. Zhang W., Doherty M., Arden N., Bannwarth B., Bijlsma J., Gunther K.P., et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 64 5 (2005) 669-681
8. Abadie E., Ethgen D., Avouac B., Bouvenot G., Branco J., Bruyere O., et al. Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis. Osteoarthritis Cartilage 12 4 (2004) 263-268
9. Bellamy N., Kirwan J., Boers M., Brooks P., Strand V., Tugwell P., et al. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol 24 4 (1997) 799-802
10. Tugwell P., Shea B., Boers M., Brooks P., Simon L.S., Strand V., et al. Evidence-Based Rheumatology. 1st edn. (2004), BMJ Books, London
11. Dougados M. Monitoring osteoarthritis progression and therapy. Osteoarthritis Cartilage 12 Suppl A (2004) S55-S60
12. Chrubasik C., Duke R.K., and Chrubasik S. The evidence for clinical efficacy of rose hip and seed: a systematic review. Phytother Res 20 1 (2006) 1-3
13. Ameye L.G., and Chee W.S. Osteoarthritis and nutrition. From nutraceuticals to functional foods: a systematic review of the scientific evidence. Arthritis Res Ther 8 4 (2006) R127
14. Winther K., Rein E., and Kharazmi A. The anti-inflammatory properties of rose-hip. Inflammopharmacology 7 1 (1999) 63-68
15. Kharazmi A., and Winther K. Rose hip inhibits chemotaxis and chemiluminescence of human peripheral blood neutrophils in vitro and reduces certain inflammatory parameters in vivo. Inflammopharmacology 7 4 (1999) 377-386
16. Larsen E., Kharazmi A., Christensen L.P., and Christensen S.B. An antiinflammatory galactolipid from rose hip (Rosa canina) that inhibits chemotaxis of human peripheral blood neutrophils in vitro. J Nat Prod 66 7 (2003) 994-995
17. Orhan D.D., Hartevioglu A., Küpeli E., and Yesilada E. In vivo anti-inflammatory and antinociceptive activity of the crude extract and fractions from Rosa canina L. fruits. J Ethnopharmacol 112 (2007) 394-400
18. Jager A.K., Eldeen I.M., and van S.J. COX-1 and -2 activity of rose hip. Phytother Res 21 12 (2007 Dec) 1251-1252
19. Winther K., Apel K., and Thamsborg G. A powder made from seeds and shells of a rose-hip subspecies (Rosa canina) reduces symptoms of knee and hip osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial. Scand J Rheumatol 34 4 (2005) 302-308
20. Moher D., Cook D.J., Eastwood S., Olkin I., Rennie D., and Stroup D.F. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354 9193 (1999) 1896-1900
21. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 17 1 (1996) 1-12
22. Huskisson E.C. Measurement of pain. J Rheumatol 9 5 (1982) 768-769
23. Christensen R., Sørensen L.B., Bartels E.M., Astrup A., and Bliddal H. Rose-hip in osteoarthritis (OA): a meta-analysis. Ann Rheum Dis 66 Suppl II (2007) 495 (Abstract)
24. Elbourne D.R., Altman D.G., Higgins J.P., Curtin F., Worthington H.V., and Vail A. Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol 31 1 (2002) 140-149
25. Curtin F., Elbourne D., and Altman D.G. Meta-analysis combining parallel and cross-over clinical trials. III: the issue of carry-over. Stat Med 21 15 (2002) 2161-2173
26. In: Deeks J.J., Higgins J.P.T., Altman D.G., Higgins J.P.T., and Green S. (Eds). Analysing and Presenting Results. 4.2.5. edn. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 (2005), John Wiley & Sons, Ltd, Chichester, UK 97-166 (Updated May 2005)
27. Altman D.G., and Bland J.M. Interaction revisited: the difference between two estimates. BMJ 326 7382 (2003) 219
28. Normand S.L. Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med 18 3 (1999) 321-359
29. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd edn. (1988), Lawrence Earlbaum Associates
30. Hedges L.V. Distribution theory for Glass's estimator of effect size and related estimators. J Educational Statistics 6 2 (1981) 107-128
31. Norman G.R., Sloan J.A., and Wyrwich K.W. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 41 5 (2003) 582-592
32. Kazis L.E., Anderson J.J., and Meenan R.F. Effect sizes for interpreting changes in health status. Med Care 27 Suppl 3 (1989) S178-S189
33. Zhang W., Doherty M., Leeb B.F., Alekseeva L., Arden N.K., Bijlsma J.W., et al. EULAR evidence based recommendations for the management of hand osteoarthritis: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 66 3 (2007) 377-388
34. Bland J.M., and Altman D.G. Statistics notes: the odds ratio. BMJ 320 7247 (2000) 1468
35. Littell R.C., Milliken G.A., Stroup W.W., Wolfinger R.D., and Schabenberger O. SAS for Mixed Models. 2nd edn. (2006), SAS Institute Inc, Cary, NC
36. Patterson H.D., and Thompson R. Recovery of inter-block information when block sizes are unequal. Biometrika 58 3 (1971) 545-554
37. Wang M.C., and Bushman B.J. Integrating Results through Meta-Analytic Review Using SAS Software. 1st edn. (1999), SAS Institute Inc, Cary, NC
38. van Houwelingen H.C., Arends L.R., and Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 21 4 (2002) 589-624
39. Cochran W.G. The combination of estimates from different experiments. Biometrics 10 1 (1954) 101-129
40. Higgins J.P., and Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 21 11 (2002) 1539-1558
41. Higgins J.P., Thompson S.G., Deeks J.J., and Altman D.G. Measuring inconsistency in meta-analyses. BMJ 327 7414 (2003) 557-560
42. Christensen R., Kristensen P.K., Bartels E.M., Bliddal H., and Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370 (2007) 1706-1713
43. Osiri M., Suarez-Almazor M.E., Wells G.A., Robinson V., and Tugwell P. Number needed to treat (NNT): implication in rheumatology clinical practice. Ann Rheum Dis 62 4 (2003) 316-321
44. Kristensen L.E., Christensen R., Bliddal H., Geborek P., Danneskiold-Samsoe B., and Saxne T. The number needed to treat for adalimumab, etanercept and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. Scand J Rheumatol 36 6 (2007) 411-417
45. Cates C.J. Simpson's paradox and calculation of number needed to treat from meta-analysis. BMC Med Res Methodol 2 (2002) 1
46. Altman D.G., and Deeks J.J. Meta-analysis, Simpson's paradox, and the number needed to treat. BMC Med Res Methodol 2 (2002) 3
47. Edwards A., Elwyn G., and Mulley A. Explaining risks: turning numerical data into meaningful pictures. BMJ 324 7341 (2002) 827-830
48. © 2000-2003 (2003), Christopher Cates.
49. Nobaek S., Johansson M.L., Molin G., Ahrne S., and Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 95 5 (2000) 1231-1238
50. Rossnagel K., and Willich S.N. Value of complementary medicine exemplified by rose-hips. Gesundheitswesen 63 6 (2001) 412-416
51. Rein E. Hansen OT, Hansen M, Assignee. Composition and method for alleviating joint pain and stiffness. United States Patent. Patent US 6,485,752 B1. 2002 Nov 26.
52. Warholm O., Skaar S., Hedman E., Mølmen H.M., and Eik L. The effects of a standardized herbal remedy made from a subtype of Rosa canina in patients with osteoarthritis: a double-blind, randomized, placebo-controlled clinical trial. Curr Ther Res Clin Exp 64 1 (2003) 21-31
53. Rein E., Kharazmi A., and Winther K. A herbal remedy, Hyben Vital (stand. powder of a subspecies of Rosa canina fruits), reduces pain and improves general wellbeing in patients with osteoarthritis - a double-blind, placebo-controlled, randomised trial. Phytomedicine 11 5 (2004) 383-391
54. Ernst E. Complementary or alternative therapies for osteoarthritis. Nat Clin Pract Rheumatol 2 2 (2006) 74-80
55. Chrubasik J.E., Roufogalis B.D., and Chrubasik S. Evidence of effectiveness of herbal antiinflammatory drugs in the treatment of painful osteoarthritis and chronic low back pain. Phytother Res 21 7 (2007) 675-683
56. Fan X., Felsövalyi A., Sivo S.A., and Keenan S.C. SAS for Monte Carlo Studies: a Guide for Quantitative Researchers. 3rd edn. (2001), SAS Institute Inc., Cary, NC, USA
57. Agresti A. A survey of exact inference for contingency tables. Stat Sci 7 1 (1992) 131-177
58. Thomas D.G. Algorithm AS 36: exact confidence limits for the odds ratio in a 2 × 2 table. Appl Stat 20 1 (1971) 105-110
59. Thompson S.G., and Pocock S.J. Can meta-analyses be trusted?. Lancet 338 8775 (1991) 1127-1130
60. Zhang W., Moskowitz R.W., Nuki G., Abramson S., Altman R.D., Arden N., et al. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage 15 9 (2007) 981-1000
61. Tubach F., Ravaud P., Baron G., Falissard B., Logeart I., Bellamy N., et al. Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Ann Rheum Dis 64 1 (2005) 29-33
62. Tubach F., Ravaud P., Baron G., Falissard B., Logeart I., Bellamy N., et al. Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state. Ann Rheum Dis 64 1 (2005) 34-37
63. Woolf A.D. Healthcare services for those with musculoskeletal conditions: a rheumatology service. Recommendations of the European Union of Medical Specialists Section of Rheumatology/European Board of Rheumatology 2006. Ann Rheum Dis 66 3 (2007) 293-301
64. Chinn S. A simple method for converting an odds ratio to effect size for use in meta-analysis. Stat Med 19 22 (2000) 3127-3131
65. Towheed T., Maxwell L., Judd M., Catton M., Hochberg M., and Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 1 (2006) CD004257
66. McAlindon T.E., LaValley M.P., Gulin J.P., and Felson D.T. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA (2000) 1469-1475
67. Richy F., Bruyere O., Ethgen O., Cucherat M., Henrotin Y., and Reginster J.Y. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 163 13 (2003) 1514-1522
68. Reginster J.Y. The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest. Arthritis Rheum 56 7 (2007) 2105-2110
69. Towheed T.E., and Anastassiades T.P. Glucosamine and chondroitin for treating symptoms of osteoarthritis: evidence is widely touted but incomplete. JAMA 283 11 (2000) 1483-1484
70. Towheed T.E. Current status of glucosamine therapy in osteoarthritis. Arthritis Rheum 49 4 (2003) 601-604
71. Vlad S.C., LaValley M.P., McAlindon T.E., and Felson D.T. Glucosamine for pain in osteoarthritis: why do trial results differ?. Arthritis Rheum 56 7 (2007) 2267-2277
72. Altman D.G., Schulz K.F., Moher D., Egger M., Davidoff F., Elbourne D., et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 134 8 (2001) 663-694
73. Gagnier J.J., Boon H., Rochon P., Moher D., Barnes J., and Bombardier C. Recommendations for reporting randomized controlled trials of herbal interventions: explanation and elaboration. J Clin Epidemiol 59 11 (2006) 1134-1149
74. Ramsey S.D., Spencer A.C., Topolski T.D., Belza B., and Patrick D.L. Use of alternative therapies by older adults with osteoarthritis. Arthritis Rheum 45 3 (2001) 222-227
75. Bjordal J.M., Ljunggren A.E., Klovning A., and Slordal L. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ 329 7478 (2004) 1317
76. Lee C., Straus W.L., Balshaw R., Barlas S., Vogel S., and Schnitzer T.J. A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis. Arthritis Rheum 51 5 (2004) 746-754
77. Towheed T.E., Maxwell L., Anastassiades T.P., Shea B., Houpt J., Robinson V., et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2 (2005) CD002946
78. Reichenbach S., Sterchi R., Scherer M., Trelle S., Burgi E., Burgi U., et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med 146 8 (2007) 580-590
79. Christensen R, Bartels EM, Astrup A, Bliddal H. Symptomatic efficacy of avocado/soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage 2007 Nov 23 [Epub ahead of print].
80. Henrotin Y., and Kurz B. Antioxidant to treat osteoarthritis: dream or reality?. Curr Drug Targets 8 2 (2007) 347-357
81. Jensen N.H. Reduced pain from osteoarthritis in hip joint or knee joint during treatment with calcium ascorbate. A randomized, placebo-controlled cross-over trial in general practice. Ugeskr Laeger 165 25 (2003) 2563-2566
82. Bjelakovic G., Nikolova D., Gluud L.L., Simonetti R.G., and Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 297 8 (2007) 842-857
83. Berlin J.A., and Colditz G.A. The role of meta-analysis in the regulatory process for foods, drugs, and devices. JAMA 281 9 (1999) 830-834
84. Rabenda V., Manette C., Lemmens R., Mariani A.M., Struvay N., and Reginster J.Y. Direct and indirect costs attributable to osteoarthritis in active subjects. J Rheumatol 33 6 (2006) 1152-1158
85. Campbell M.J., Julious S.A., and Altman D.G. Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons. BMJ 311 7013 (1995) 1145-1148
86. Bellamy N., Buchanan W.W., Goldsmith C.H., Campbell J., and Stitt L.W. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15 12 (1988) 1833-1840
87. Roos E.M., and Toksvig-Larsen S. Knee injury and Osteoarthritis Outcome Score (KOOS) - validation and comparison to the WOMAC in total knee replacement. Health Qual Life Outcomes 1 1 (2003) 17
88. Lequesne M.G., Mery C., Samson M., and Gerard P. Indexes of severity for osteoarthritis of the hip and knee. Validation - value in comparison with other assessment tests. Scand J Rheumatol Suppl 65 (1987) 85-89
89. Pham T., van der H.D., Altman R.D., Anderson J.J., Bellamy N., Hochberg M., et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage 12 5 (2004) 389-399
90. Moher D., Schulz K.F., and Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 285 15 (2001) 1987-1991